Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

StreakGeek Jul. 2 at 10:13 PM

$ABBV in a flow state

0 · Reply

SwingTraderPro1 Jul. 2 at 9:54 PM

Just THIS WEEK I delivered over 8,128% in gains -completely free. Yes, 8,128% in ONE week. No paywall. I GAVE YOU the setups before the move happened $MCD 02 JUL 26 $275 CALL FOR 2,103% $ABBV 02 JUL 26 $255 CALL FOR 1,679% $AAPL 06 JUL 26 $295 CALL FOR 1,100% $LTH 17 JUL 26 $40 CALL FOR 525% $MSFT 29 JUN 26 $360 PUT FOR 446% turn post notifications on to get an early entry i do not need to charge you because i actually make money trading

0 · Reply

ETAlpha Jul. 2 at 9:39 PM

$MRK $ABBV Annoying to watch ABBV and others rip this week while MRK dragged. Major underperformance, but sector rotation is real. Weekend prediction: MRK is heavily oversold on the daily. Expecting a gap up or a fast relief bounce early next week to catch up with big pharma. Watching closely.

0 · Reply

bzb711 Jul. 2 at 9:21 PM

$ABBV It’s important to have a diversified portfolio. Looking forward to Financial, Healthcare, and Industrial sectors in the second half of the year.

0 · Reply

EddieHayes Jul. 2 at 7:40 PM

On 6/15/2026 we rebalanced the core portfolio ahead of a broader rotation outside tech. Since then: S&P 500: -0.71% Core portfolio: +3.10% Outperformance is coming from staying balanced, not concentrated. The book is intentionally diversified: large caps like $AMZN, healthcare exposure like $ABBV, financials like $V, cyclicals like $DE and $XOM, plus selective higher-beta names like HOOD and SOFI, alongside laggards like ISRG and software exposure likeMDB. This is not a “kill the AI trade” view. It’s a positioning shift for a choppier macro regime where leadership rotates more frequently. AI isn’t dead — it’s just not a straight-line trade anymore. Stay balanced, size properly, and adapt to rotation instead of chasing momentum.

0 · Reply

ThomasParker012 Jul. 2 at 7:15 PM

A strong player in the pharma sector. Keeping an eye on their new drug pipeline. $ABBV

0 · Reply

SunnySeed Jul. 2 at 7:02 PM

$SLS $ABBV Been saying this for a year and soon we will find out!

0 · Reply

JFDI Jul. 2 at 6:59 PM

$ABBV AB/CD up

0 · Reply

CEOofstocks Jul. 2 at 6:29 PM

$SLS $ABBV

0 · Reply

Cap_00 Jul. 2 at 6:24 PM

$VKTX $ABBV is time to join the obesity space.

0 · Reply

House committee opens probe into Merck, AbbVie China drug trials, Reuters says

MRK

Jun 30, 2026, 6:02 AM EDT - 2 days ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

2026-06-29T20:20:34.000Z - 3 days ago

AbbVie reports ‘positive’ results from Phase 3 EPCORE DLBCL-4 trial

GMAB

$AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma$

Jun 29, 2026, 4:15 PM EDT - 3 days ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

2026-06-29T09:20:22.000Z - 3 days ago

AbbVie announces CHMP opinion recommending approval of upadacitinib for AA

Jun 29, 2026, 3:10 AM EDT - 3 days ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:00 AM EDT - 3 days ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

2026-06-26T20:55:10.000Z - 6 days ago

AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease

Jun 26, 2026, 4:50 PM EDT - 6 days ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 2:39 PM EDT - 6 days ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

Jun 26, 2026, 8:00 AM EDT - 6 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 24, 2026, 12:51 PM EDT - 8 days ago

AbbVie's $11 Billion Immunology Bet

APGE

Jun 24, 2026, 8:00 AM EDT - 8 days ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

2026-06-23T12:54:44.000Z - 9 days ago

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

2026-06-23T12:22:00.000Z - 9 days ago

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

APGE

Jun 23, 2026, 8:00 AM EDT - 9 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

2026-06-23T11:29:50.000Z - 9 days ago

Apogee Therapeutics moved to No Rating at BofA

APGE

2026-06-23T11:04:51.000Z - 9 days ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE

2026-06-23T10:24:35.000Z - 9 days ago

AbbVie announces European Commission approval for Skyrizi

2026-06-23T10:00:54.000Z - 9 days ago

AbbVie announces European Commission approval of Maviret

2026-06-23T09:46:03.000Z - 9 days ago

AbbVie announces EU approval of Skyrizi for pediatric patients

Jun 23, 2026, 5:00 AM EDT - 9 days ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 3:00 AM EDT - 9 days ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

2026-06-22T21:55:09.000Z - 10 days ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

APGE EVMN

Jun 22, 2026, 10:30 AM EDT - 10 days ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

Jun 22, 2026, 10:15 AM EDT - 10 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

Jun 22, 2026, 9:00 AM EDT - 10 days ago

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 10 days ago

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 10 days ago

AbbVie Press release: M&A announcement

2026-06-22T12:24:03.000Z - 10 days ago

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

APGE REGN

Jun 22, 2026, 7:42 AM EDT - 10 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Jun 22, 2026, 7:06 AM EDT - 10 days ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

Jun 22, 2026, 7:04 AM EDT - 10 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

Jun 22, 2026, 7:00 AM EDT - 10 days ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

Jun 20, 2026, 12:11 PM EDT - 12 days ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

Jun 19, 2026, 11:17 AM EDT - 13 days ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

Jun 18, 2026, 4:05 PM EDT - 14 days ago

AbbVie Declares Quarterly Dividend

Jun 16, 2026, 8:00 AM EDT - 16 days ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 12, 2026, 3:00 AM EDT - 20 days ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 11, 2026, 7:14 AM EDT - 21 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

Jun 10, 2026, 11:47 AM EDT - 22 days ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 9, 2026, 10:40 AM EDT - 23 days ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 24 days ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 3, 2026, 7:04 PM EDT - 4 weeks ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 3:30 AM EDT - 4 weeks ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

Jun 2, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 29, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 27, 2026, 6:18 PM EDT - 5 weeks ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 3:33 PM EDT - 5 weeks ago

US FDA approves AbbVie's rare blood cancer drug

May 22, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 21, 2026, 6:46 PM EDT - 6 weeks ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 4:10 PM EDT - 6 weeks ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 13, 2026, 2:20 PM EDT - 7 weeks ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 5, 2026, 8:05 AM EDT - 2 months ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

May 1, 2026, 3:05 PM EDT - 2 months ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 10:03 AM EDT - 2 months ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 2 months ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 7:50 AM EDT - 2 months ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 2 months ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 7:00 AM EDT - 2 months ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 27, 2026, 8:05 AM EDT - 2 months ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:05 PM EDT - 2 months ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

StreakGeek Jul. 2 at 10:13 PM

$ABBV in a flow state

0 · Reply

SwingTraderPro1 Jul. 2 at 9:54 PM

0 · Reply

ETAlpha Jul. 2 at 9:39 PM

0 · Reply

bzb711 Jul. 2 at 9:21 PM

$ABBV It’s important to have a diversified portfolio. Looking forward to Financial, Healthcare, and Industrial sectors in the second half of the year.

0 · Reply

EddieHayes Jul. 2 at 7:40 PM

0 · Reply

ThomasParker012 Jul. 2 at 7:15 PM

A strong player in the pharma sector. Keeping an eye on their new drug pipeline. $ABBV

0 · Reply

SunnySeed Jul. 2 at 7:02 PM

$SLS $ABBV Been saying this for a year and soon we will find out!

0 · Reply

JFDI Jul. 2 at 6:59 PM

$ABBV AB/CD up

0 · Reply

CEOofstocks Jul. 2 at 6:29 PM

$SLS $ABBV

0 · Reply

Cap_00 Jul. 2 at 6:24 PM

$VKTX $ABBV is time to join the obesity space.

0 · Reply

55X_ROI_Q1_2026 Jul. 2 at 6:22 PM

$SLS "6 to 8 months is recently approved agents". Dr. Jamy Dr. Levy, "survival is not durable on Ven + HMA's". Ven + Aza (HMA) FAILED 3 Large Phase 3 Trials Conducted by $ABBV -it is not complicated VIALE-M Phase 3 Trial for AML Patients in First REMISSION (CR1) FAILED VIALE-T Phase 3 Trial for Post Transplant AML Maintenance FAILED Gps has proven effective in Preventing Relapse and extending Survival in ALL Prior Trials, Including 2 Phase 2 Trials for AML Remission Maintenance with 2x and 4x Survival Benefit - No Toxicity, easy to administer ... it is not complicated.

0 · Reply

StreakGeek Jul. 2 at 5:46 PM

$MCD $CPRT $ABBV $LMT life

0 · Reply

kagrawala Jul. 2 at 5:25 PM

$ABBV i remember buying this for close to 65 in COVID 😳

0 · Reply

SwingTraderPro1 Jul. 2 at 4:11 PM

Since the 6/15/2026 rebalance, we’ve been leaning into rotation outside pure tech-and the tape has started to reflect it. $SPY is down ~0.7% since then and still choppy, while our diversified core basket is up ~3.1% over the same window. Outperformance is coming from balance, not concentration. Mix includes Mag 7 exposure like $AMZN, healthcare names like $ABBV, financials like $V, plus select volatility in $HOOD / SOFI / CRWV, and cyclical hedges via DE and XOM with defensives like KO. AI isn’t dead-but positioning matters more than narrative right now.

0 · Reply